INDOCO Indoco Remedies Q4 FY26 results (Jan–Mar 2026) and concall
Indoco Remedies reported a positive Q4 FY26 performance after six quarters, primarily driven by robust growth in international formulations and regulated markets. While the India business faced seasonal headwinds, the company achieved significant ANDA approvals and improved prescription rankings. Key concerns include elongated receivables, high debt, and macroeconomic pressures, alongside challenges in the API business due to ongoing product validations.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 22.1%, net profit up 41.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 411 | 390 | 440 | 485 | 445 +8% | 476 +22% |
| EBITDA | 12 | -1 | 18 | 43 | 32 +167% | 50 +5100% |
| Net profit | -28 | -41 | -36 | -9 | -29 −4% | -24 +41% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
